cPLA2–Inhibitor (stoPLA) – New compounds for the topical treatment of skin inflammation
Novel group of nonsteroidal anti-inflammatory drugs: The new class of heteroaryl-substituted acetone derivatives inhibits effectively the cytosolic phospholipase A2 (cPLA2).
The compounds interact with the synthesis of prosta-glandins and leukotrienes and reduce inflammatory processes. The substances have an excellent solubility profile. The heteroaryl-substituted acetone derivatives provide the platform for the development of new pharmaceutical products for the treatment of inflammatory diseases of the skin, such as psoriasis and atopic dermatitis.
Further Information: PDF
PROvendis GmbH
Phone: +49 (0)208/94105 10
Contact
Dipl.-Ing. Alfred Schillert
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Breakthrough in magnetism that could transform quantum computing and superconductors
Researchers discover new magnetic and electronic properties in kagome magnet thin films. A discovery by Rice University physicists and collaborators is unlocking a new understanding of magnetism and electronic interactions…
NASA to launch innovative solar coronagraph to Space Station
NASA’s Coronal Diagnostic Experiment (CODEX) is ready to launch to the International Space Station to reveal new details about the solar wind including its origin and its evolution. Launching in…
Boosting efficiency in mining with AI and automation
“Doing instead of procrastinating”. This is the AI strategy presented by Prof. Constantin Haefner, Director of the Fraunhofer Institute for Laser Technology ILT, at the “AKL’24 – International Laser Technology…